BRIEF published on 05/05/2025 at 09:10, 10 months 17 days ago BioNxt Solutions Secures Patent Acceptance from Eurasian Patent Organization Innovation Autoimmune Diseases Drug Delivery BioNxt Solutions Eurasian Patent
BRIEF published on 05/05/2025 at 09:10, 10 months 17 days ago BioNxt Solutions obtient l'acceptation de son brevet auprès de l'Organisation eurasienne des brevets Innovation Maladies Auto-immunes Solutions BioNxt Administration De Médicaments Brevet Eurasien
PRESS RELEASE published on 05/05/2025 at 09:05, 10 months 17 days ago BioNxt Solutions Reports Expanded Patent Protection from the Eurasian Patent Organization BioNxt Solutions Inc. announces acceptance of its first national level patent filing by Eurasian Patent Organization, covering sublingual drug delivery for neurodegenerative diseases BioNxt Solutions Inc. Patent Filing Neurodegenerative Diseases Sublingual Delivery Eurasian Patent Organization
BRIEF published on 05/02/2025 at 01:55, 10 months 21 days ago BioNxt Solutions Delays 2024 Annual Financial Statement Filing Management Cease Trade Order Healthcare Innovation Financial Statements Delay Annual Filings BioNxt Solutions
BRIEF published on 05/02/2025 at 01:55, 10 months 21 days ago BioNxt Solutions retarde le dépôt de ses états financiers annuels pour 2024 Dépôts Annuels Solutions BioNxt Retard Des États Financiers Innovation Dans Le Domaine Des Soins De Santé Ordonnance De Cessation D'opérations De La Direction
PRESS RELEASE published on 05/02/2025 at 01:50, 10 months 21 days ago BioNxt Solutions Announces Delay In Filing 2024 Annual Financial Statements BioNxt Solutions Inc. announces delay in filing annual financial statements for year ended December 31, 2024. Company working on completing filings by June 28, 2025, under management cease trade order Financial Statements Management Cease Trade Order BioNxt Solutions Inc. Delay Regulatory Authorities
BRIEF published on 04/23/2025 at 09:10, 10 months 29 days ago BioNxt Solutions Advances in MS Treatment Study Multiple Sclerosis Cladribine Drug Delivery Innovation BioNxt Solutions Bioequivalence Study
BRIEF published on 04/23/2025 at 09:10, 10 months 29 days ago BioNxt Solutions progresse dans une étude sur le traitement de la sclérose en plaques Sclérose En Plaques Cladribine Solutions BioNxt Étude De Bioéquivalence Innovation En Matière D'administration De Médicaments
PRESS RELEASE published on 04/23/2025 at 09:05, 10 months 29 days ago BioNxt Solutions Prepares for Human Bioequivalence Study For MS BioNxt Solutions Inc. reports advanced preparation for human bioequivalence study of BNT23001, a novel sublingual thin-film Cladribine formulation for Multiple Sclerosis treatment BioNxt Solutions Inc. Multiple Sclerosis Treatment Sublingual Thin-Film BNT23001 Human Bioequivalence Study
BRIEF published on 03/15/2025 at 00:05, 1 year ago BioNxt Solutions Closes Final Tranche of Convertible Debenture Offering Private Placement Convertible Debenture Warrants Financing BioNxt Solutions
Published on 03/23/2026 at 08:00, 13 minutes ago ABRIDGED, PRELIMINARY AND UNAUDITED QUARTERLY AND FULL YEAR RESULTS AND DETAILS OF MANAGEMENT CONFERENCE Call for the Fourth Quarter and Full Year Ended December 31, 2025 ("The Quarter" or "Q4 2025" and "FY 2025" Respectively)
Published on 03/23/2026 at 02:00, 6 hours 13 minutes ago FutureGen Industries Announces Open Market Investments
Published on 03/23/2026 at 08:00, 13 minutes ago Zentra Group plc: Unaudited interim report for the six months ended 31 December 2025
Published on 03/23/2026 at 08:00, 13 minutes ago Notification of the Greenshoe-Option and Stabilization Measures in accordance with Art. 5 (4)(b), (5) and (6) of Reg. (EU) 596/2014 and Art. 8 (f) and Art. 6 (3) Comm. Delegated Reg. (EU) 2016/1052
Published on 03/23/2026 at 07:46, 27 minutes ago Delivery Hero to sell Taiwan food delivery operations to Grab for USD 600 million
Published on 03/23/2026 at 07:30, 43 minutes ago Nordex Group receives new order from Serbia for 70 MW
Published on 03/23/2026 at 08:10, 3 minutes ago Entrée en négociations exclusives de cession de la participation dans Winncare
Published on 03/20/2026 at 19:00, 2 days 13 hours ago AXA - Conditions for availability or consultation of information relating to AXA’s Shareholders’ Meeting of April 30, 2026
Published on 03/20/2026 at 19:00, 2 days 13 hours ago AXA - Modalités de mise à disposition ou de consultation des informations relatives à l’Assemblée Générale du 30 avril 2026
Published on 03/20/2026 at 18:15, 2 days 13 hours ago Publication of AXA’s 2025 Universal Registration Document
Published on 03/20/2026 at 18:15, 2 days 13 hours ago Mise à disposition du Document d’Enregistrement Universel 2025 d’AXA
